Oculis Holding AG Ordinary Shares reports a Return on Equity (ROE) of -48.49%.

What is OCS's dividend yield?

Oculis Holding AG Ordinary Shares offers a dividend yield of 0.00%.

What is OCS's Quality Score?

Our AI rates OCS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OCS?

Our AI Timing Score for OCS is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OCS belong to?

Oculis Holding AG Ordinary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Oculis Holding AG (OCS) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

OCS AI Analysis Summary

Our AI summary for OCS: Oculis Holding AG Ordinary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -48.49%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

OCS

Oculis Holding AG Ordinary Shares

US:NASDAQ STOCK Healthcare >> Biotechnology News 86

USD 11.99

0.10 (0.84%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-48.5%

ROE

-39.1%

ROA

0.00%

Div Yield

OCULIS HOLDING AG ORDINARY SHARES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.99 Price 0.10 (0.84%) Day Change	NEWS SCORE: 86

OCS, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	86
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	11.99
PBV / Sector	3.66 / 44,022.72
Earning Per Share	-1.59

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	3.83 M GREAT
Average 1W Daily Value	3.36 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-18,861.29 / 98.24
NPM Average (%) / Sector	-11,416.32 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-39.08 / 185,260.96
ROA Average (%) / Sector	-66.49 / 36,684.70
ROA Change Average (%) / Sector	-20.01 / 422,221.66
ROE (%) / Sector	-48.49 / 243,762.23
ROE Average (%) / Sector	-53.75 / 48,758.47
ROE Change Average (%) / Sector	-93.66 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:38
Symbol	OCS
Name	OCULIS HOLDING AG ORDINARY SHARES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	60.39 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	718.01 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Bahnhofstrasse 20, Zug, Switzerland, 6300

Phone: 41 41 711 3960

Website: https://oculis.com

Employees: 60

Sector: Healthcare >> Biotechnology

Description: Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.